Skip to content
Lokelma(sodium zirconium cyclosilicate)
Lokelma (sodium zirconium cyclosilicate) is a small molecule pharmaceutical. Sodium zirconium cyclosilicate was first approved as Lokelma on 2018-03-22. It is used to treat hyperkalemia in the USA. It has been approved in Europe to treat hyperkalemia.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Lokelma
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sodium zirconium cyclosilicate
Tradename
Company
Number
Date
Products
LOKELMAAstraZenecaN-207078 RX2018-05-18
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
lokelmaNew Drug Application2023-06-08
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hyperkalemiaHP_0002153D006947E87.5
Agency Specific
FDA
EMA
Expiration
Code
SODIUM ZIRCONIUM CYCLOSILICATE, LOKELMA, ASTRAZENECA
2023-05-18NCE
2023-04-24M-261
Patent Expiration
Patent
Expires
Flag
FDA Information
Sodium Zirconium Cyclosilicate, Lokelma, Astrazeneca
95922532035-10-14DPU-2312
103000872035-10-14DPU-2312
88772552033-10-22DP
99138602033-10-22DPU-2312
106953652033-10-22DP
88021522032-04-19DP
88087502032-02-10U-2312
98445672032-02-10U-2312
98616582032-02-10U-2312
103354322032-02-10U-2312
103987302032-02-10U-2312
104135692032-02-10DP
114066622032-02-10DP
ATC Codes
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AE: Drugs for treatment of hyperkalemia and hyperphosphatemia
— V03AE10: Sodium zirconium cyclosilicate
HCPCS
No data
Clinical
Clinical Trials
29 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HyperkalemiaD006947HP_0002153E87.534145126
Chronic renal insufficiencyD051436N181—3127
Heart failureD006333EFO_0003144I50—211—4
Type 2 diabetes mellitusD003924EFO_0001360E11—1—1—2
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AcidosisD000138EFO_1000014E87.2——1——1
Secondary hyperparathyroidismD006962EFO_1001173——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSODIUM ZIRCONIUM CYCLOSILICATE
INN—
Description
Sodium zirconium cyclosilicate, sold under the brand name Lokelma, is a medication used to treat high blood potassium. Onset of effects occurs in one to six hours. It is taken by mouth.
Classification
Small molecule
Drug classquaternary ammonium derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O.O[Si](O)(O)O.O[Si](O)(O)O.O[Si](O)(O)O.[Na+].[Na+].[O-][Zr]([O-])(O)(O)(O)O
Identifiers
PDB—
CAS-ID242800-27-7
RxCUI—
ChEMBL IDCHEMBL3301592
ChEBI ID—
PubChem CID—
DrugBankDB14048
UNII ID—
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Lokelma - AstraZeneca
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 389 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
44,065 adverse events reported
View more details